论文部分内容阅读
目的：证实国产人基因重组红细胞生成素（ｒＨｕＥＰＯ）纠正终末期肾病（ＥＳＲＤ）患者肾性贫血的疗效。方法：５５例ＥＳＲＤ合并肾性贫血患者应用国产ｒＨｕＥＰＯ治疗１２周～２４周，给药方式随机分为皮下或静脉注射。结果：５４例中，４例中途退出。５１例用药前后自身对比显示：血红蛋白、红细胞压积、网织红细胞从给药第２周起显著升高（Ｐ＜００１）；白细胞、血小板、肝功能、肾功能、血清离子无明显改变（Ｐ＞００５）。应用药物剂量１２８２±２６１Ｕ／（ｋｇ·周）的疗效判定：显效率５２９％，有效率３３３％，无效率１３７％。副作用有头痛、低热、高血压等，发生率１２７％（７／５５）。结论：国产ｒＨｕＥＰＯ能安全有效纠正肾性贫血，副作用轻微。
Objective: To verify the efficacy of domestic recombinant human erythropoietin (rHuEPO) in the treatment of renal anemia in patients with end-stage renal disease (ESRD). Methods: 55 patients with ESRD complicated with renal anemia were treated with domestic rHuEPO for 12 weeks to 24 weeks. The modes of administration were randomly divided into subcutaneous or intravenous injection. Results: In 54 cases, 4 patients quit midway. The self-comparison of 51 patients before and after treatment showed that hemoglobin, hematocrit and reticulocyte were significantly increased from the second week after administration (P <001); no significant changes were found in white blood cells, platelets, liver function, renal function and serum ions (P> 005). Application of drug dose 128 2 26 1U / (kg · weeks) of the efficacy of judgment: markedly effective rate of 52 9%, effective rate was 333%, ineffective rate of 13 7%. Side effects have headache, fever, high blood pressure, the incidence of 12 7% (7/55). Conclusion: Domestic rHuEPO can safely and effectively correct renal anemia with minor side effects.